loading
Bridgebio Pharma Inc stock is traded at $34.87, with a volume of 1.97M. It is down -0.20% in the last 24 hours and up +3.08% over the past month. BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$34.90
Open:
$35
24h Volume:
1.97M
Relative Volume:
0.82
Market Cap:
$6.60B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-14.47
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
+11.92%
1M Performance:
+3.08%
6M Performance:
+42.75%
1Y Performance:
-6.40%
1-Day Range:
Value
$33.86
$35.41
1-Week Range:
Value
$30.50
$35.41
52-Week Range:
Value
$21.62
$37.81

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
Name
Bridgebio Pharma Inc
Name
Phone
(650) 391-9740
Name
Address
3160 PORTER DR., PALO ALTO, CA
Name
Employee
556
Name
Twitter
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
BBIO's Discussions on Twitter

Compare BBIO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BBIO
Bridgebio Pharma Inc
34.91 6.60B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.15 117.87B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
679.09 73.64B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
643.08 38.85B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.22 33.20B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
122.36 28.73B 3.30B -501.07M 1.03B -2.1146

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-16-24 Initiated Scotiabank Sector Outperform
Oct-03-24 Initiated Oppenheimer Perform
Sep-04-24 Initiated Piper Sandler Overweight
Mar-21-24 Resumed Raymond James Outperform
Jan-31-24 Initiated BMO Capital Markets Market Perform
Dec-08-23 Initiated Wells Fargo Overweight
Nov-07-23 Initiated Citigroup Buy
Oct-24-23 Initiated Cantor Fitzgerald Overweight
Jul-18-23 Downgrade Jefferies Buy → Hold
Apr-19-23 Initiated Evercore ISI Outperform
Feb-06-23 Initiated Cowen Outperform
Dec-27-21 Reiterated Mizuho Buy
Dec-27-21 Reiterated SVB Leerink Outperform
Sep-10-21 Upgrade BofA Securities Neutral → Buy
May-21-21 Initiated UBS Buy
Mar-22-21 Reiterated Goldman Buy
Feb-22-21 Resumed JP Morgan Overweight
Feb-09-21 Resumed Goldman Buy
Jan-11-21 Reiterated H.C. Wainwright Buy
Dec-10-20 Reiterated H.C. Wainwright Buy
Jun-25-20 Initiated BofA/Merrill Neutral
May-19-20 Initiated BTIG Research Buy
Apr-13-20 Initiated H.C. Wainwright Buy
Feb-19-20 Initiated Mizuho Buy
Jul-26-19 Initiated Raymond James Outperform
Jul-22-19 Initiated BMO Capital Markets Outperform
Jul-22-19 Initiated Goldman Buy
Jul-22-19 Initiated JP Morgan Overweight
Jul-22-19 Initiated Jefferies Buy
Jul-22-19 Initiated Piper Jaffray Overweight
Jul-22-19 Initiated SVB Leerink Outperform
View All

Bridgebio Pharma Inc Stock (BBIO) Latest News

pulisher
Feb 15, 2025

BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 7.2%What's Next? - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Scotiabank Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

(BBIO) Trading Signals - Stock Traders Daily

Feb 15, 2025
pulisher
Feb 14, 2025

Harvey Capital Management Inc. Takes $354,000 Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

HC Wainwright Reaffirms Buy Rating for BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

BridgeBio Pharma to Report Fourth Quarter and Full Year - GlobeNewswire

Feb 14, 2025
pulisher
Feb 13, 2025

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025 - The Manila Times

Feb 13, 2025
pulisher
Feb 13, 2025

BridgeBio price target raised to $49 from $48 at Scotiabank - Yahoo Finance

Feb 13, 2025
pulisher
Feb 13, 2025

BridgeBio’s receives EU approval for its Transthyretin Amyloidosis treatment - MSN

Feb 13, 2025
pulisher
Feb 12, 2025

BridgeBio shares rise on Scotiabank price target boost - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

BridgeBio shares rise on Scotiabank price target boost By Investing.com - Investing.com South Africa

Feb 12, 2025
pulisher
Feb 12, 2025

BridgeBio gets EU nod for ATTR cardiomyopathy drug - pharmaphorum

Feb 12, 2025
pulisher
Feb 11, 2025

BridgeBio Pharma Announces EU Approval Of BEYONTTRA For Treatment Of ATTR-CM - Nasdaq

Feb 11, 2025
pulisher
Feb 11, 2025

BridgeBio wins EU approval for Beyonttra for ATTR-CM - The Pharma Letter

Feb 11, 2025
pulisher
Feb 11, 2025

Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK - BioPharma Dive

Feb 11, 2025
pulisher
Feb 11, 2025

BridgeBio Pharma Says Beyonttra Gets EU Marketing Approval for Transthyretin Amyloidosis - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

BridgeBio announces EC marketing authorization for BETONTTRA - TipRanks

Feb 11, 2025
pulisher
Feb 11, 2025

BEYONTTRA™ (acoramidis), the First Near Complete TTR - GlobeNewswire

Feb 11, 2025
pulisher
Feb 11, 2025

BBIO Secures Major EU Win: Revolutionary Heart Drug Shows 42% Mortality Reduction - StockTitan

Feb 11, 2025
pulisher
Feb 10, 2025

BridgeBio's Heart Disease Drug Meets Late-stage End Points - BW Healthcare World

Feb 10, 2025
pulisher
Feb 08, 2025

Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts - Insider Monkey

Feb 08, 2025
pulisher
Feb 08, 2025

BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 5.5% Following Insider Selling - MarketBeat

Feb 08, 2025
pulisher
Feb 07, 2025

BridgeBio: Post Attruby Approval, Shares Don't Look Such Good ValueRating Downgrade - Seeking Alpha

Feb 07, 2025
pulisher
Feb 05, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Update - MarketBeat

Feb 05, 2025
pulisher
Feb 04, 2025

How To Trade (BBIO) - Stock Traders Daily

Feb 04, 2025
pulisher
Feb 04, 2025

BBIO (BridgeBio Pharma) Operating Cash Flow per Share : $-2.50 (TTM As of Sep. 2024) - GuruFocus.com

Feb 04, 2025
pulisher
Feb 04, 2025

Why BridgeBio Pharma Inc. (BBIO) Crashed on Monday - Insider Monkey

Feb 04, 2025
pulisher
Feb 03, 2025

Analysts Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) PT at $49.00 - MarketBeat

Feb 03, 2025
pulisher
Feb 03, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 326,932 Shares - MarketBeat

Feb 03, 2025
pulisher
Feb 02, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson Sells 68,000 Shares - MarketBeat

Feb 02, 2025
pulisher
Feb 01, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Major Shareholder Sells $106,989,998.40 in Stock - MarketBeat

Feb 01, 2025
pulisher
Feb 01, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Moody Aldrich Partners LLC - MarketBeat

Feb 01, 2025
pulisher
Jan 31, 2025

Andreas Halvorsen Reduces Stake in BridgeBio Pharma Inc - GuruFocus.com

Jan 31, 2025
pulisher
Jan 31, 2025

BridgeBio Pharma Insider Sold Shares Worth $2,467,761, According to a Recent SEC Filing - Marketscreener.com

Jan 31, 2025
pulisher
Jan 29, 2025

Is BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025? - Insider Monkey

Jan 29, 2025
pulisher
Jan 27, 2025

BBIO (BridgeBio Pharma) Cash Flow for Dividends : $0.0 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 27, 2025
pulisher
Jan 27, 2025

BBIO (BridgeBio Pharma) EBITDA : $-350.3 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 27, 2025
pulisher
Jan 27, 2025

Why BridgeBio Pharma (BBIO) Is Skyrocketing Now - MSN

Jan 27, 2025
pulisher
Jan 26, 2025

BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 25, 2025

14,302 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Acquired by Atomi Financial Group Inc. - MarketBeat

Jan 25, 2025
pulisher
Jan 24, 2025

(BBIO) Trading Report - Stock Traders Daily

Jan 24, 2025
pulisher
Jan 24, 2025

Equities Analysts Set Expectations for BBIO FY2025 Earnings - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Research Analysts Issue Forecasts for BBIO FY2025 Earnings - Defense World

Jan 24, 2025

Bridgebio Pharma Inc Stock (BBIO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Bridgebio Pharma Inc Stock (BBIO) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
VIKING GLOBAL INVESTORS LP
10% Owner
Jan 31 '25
Sale
34.90
3,065,616
106,989,998
22,055,375
STEPHENSON BRIAN C
Secretary, Treasurer & CFO
Jan 28 '25
Option Exercise
17.00
68,000
1,156,000
161,758
STEPHENSON BRIAN C
Secretary, Treasurer & CFO
Jan 28 '25
Sale
36.29
68,000
2,467,761
93,758
Kumar Neil
Chief Executive Officer
Jan 28 '25
Sale
36.29
326,932
11,863,381
5,371,515
Kumar Neil
Chief Executive Officer
Jan 29 '25
Sale
36.35
273,068
9,925,269
5,098,447
$32.73
price up icon 1.16%
$81.10
price up icon 2.19%
$20.79
price down icon 2.83%
$373.63
price up icon 0.82%
biotechnology ONC
$238.71
price up icon 3.03%
$122.29
price up icon 2.09%
Cap:     |  Volume (24h):